Results 131 to 140 of about 26,259 (260)

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino   +13 more
wiley   +1 more source

Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species. [PDF]

open access: yesEmerg Microbes Infect
Zhou J   +15 more
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera   +24 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

open access: yesThe FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture   +3 more
wiley   +1 more source

Infections after bispecific antibodies in B-cell lymphomas. [PDF]

open access: yesBlood Adv
Kim DH   +9 more
europepmc   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

open access: yesHaemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita   +2 more
wiley   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila   +17 more
wiley   +1 more source

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma. [PDF]

open access: yesBlood Cancer J
Chohan KL   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy